预约演示
更新于：2026-10-21
Vadimezan
伐地美生
更新于：2026-10-21
概要
基本信息
登录后查看时间轴
结构/序列
分子式C17H14O4 |
InChIKeyXGOYIMQSIKSOBS-UHFFFAOYSA-N |
CAS号117570-53-3 |
关联
22
项与 伐地美生 相关的临床试验NCT01071928
A Phase II Trial of Docetaxel Plus ASA404 as Second-Line Therapy in Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU09-144
EUCTR2009-016834-28-BE
An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trials
NCT01278758
A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function
100 项与 伐地美生 相关的临床结果
登录后查看更多信息
100 项与 伐地美生 相关的转化医学
登录后查看更多信息
100 项与 伐地美生 相关的专利（医药）
登录后查看更多信息
396
项与 伐地美生 相关的文献（医药）2027-02-01JOURNAL OF ETHNOPHARMACOLOGY
Zuogui Pill alleviates chemotherapy-induced ovarian aging and oogonial stem cell injury by modulating cGAS-STING-mediated inflammatory signaling
Article
作者: Zhu, Ling ; Zheng, Yunling ; An, Junyi ; Liang, Yunyi ; Li, Zuang ; Wang, Yixuan ; Zou, Yuxin ; Zeng, Lihua
ETHNOPHARMACOLOGICAL RELEVANCE:
Zuogui Pill (ZGP), a representative prescription for tonifying kidney and replenishing essence, is commonly employed in treating ovarian aging and related reproductive disorders.
AIM OF THE STUDY:
To investigate the effects of ZGP on chemotherapy-induced ovarian aging and oogonial stem cell (OSC) injury, with an emphasis on the involvement of cGAS-STING signaling.
MATERIALS AND METHODS:
UPLC-Q-TOF-MS was used to identify representative constituents of Zuogui Pill (ZGP). A chemotherapy-induced ovarian aging model was established by administering cyclophosphamide (CTX, 120 mg/kg) via intraperitoneal injection, and mice received oral ZGP treatment for six weeks. Phosphoramide mustard cyclohexanamine (PM)-exposed OSCs served as an in vitro model and were treated with ZGP-containing serum. The involvement of STING signaling was further examined through STING knockdown and pharmacological STING activation with DMXAA. Hematoxylin-eosin staining, ELISA, immunohistochemistry, Western blot, qPCR, and immunofluorescence were performed to evaluate ovarian histomorphology, serum sex hormones, inflammatory responses, the expression of germline- and stem cell-associated markers, apoptosis-related changes, and pathway activation.
RESULTS:
ZGP improved serum sex hormone profiles, increased ovarian index, and promoted follicular development in CTX-treated mice. In both animal and cellular models, ZGP attenuated cGAS-STING pathway activation and reduced inflammatory cytokine and interferon-stimulated gene expression. ZGP also increased the expression of Oct4, MVH, and Fragilis, reduced the expression of P21, and ameliorated alterations in apoptosis-related proteins. STING knockdown alleviated PM-induced OSC injury, whereas ZGP attenuated DMXAA-stimulated STING activation.
CONCLUSION:
ZGP alleviated chemotherapy-induced ovarian aging and OSC injury, with improvements in ovarian morphology, sex hormone profiles, and germline- and stem cell-associated marker expression, as well as reduction in inflammatory and apoptosis-related changes. The effects of ZGP may involve modulation of cGAS-STING-mediated inflammatory signaling. These findings provide further insight into the potential clinical application of ZGP in chemotherapy-induced ovarian aging.
2027-01-01PHYTOCHEMISTRY
Sesquiterpene lactones from Centipeda minima and their STING inhibitory activities
Article
作者: Ji, Jianxin ; Zhang, Hai ; Lin, Yaning ; Shi, Yuying ; Liu, Xiaofang ; Yang, Shan ; Wang, Lun ; Shen, Xiaofei
Five undescribed sesquiterpene lactones, named minimolides M-Q (1-5), along with twelve known analogues (6-17), were isolated from the whole plants of Centipeda minima. The structures of these previously undescribed compounds were elucidated using extensive spectroscopic methods (IR, UV, HRESIMS, and NMR), and the complete structures of 1 and 2 were further confirmed by single-crystal X-ray diffraction analysis. Among the isolates, compounds 5, 10, 13, 14, 16, and 17 exhibited STING inhibitory activity in DMXAA-stimulated RAW264.7-Lucia-ISG cells. Subsequent western blotting and RT-qPCR assays revealed that compound 5 suppressed DMXAA- and cyclic GMP-AMP (cGAMP)-induced phosphorylation of the STING-TBK1-IRF3/p65 signaling cascade, thereby inhibiting STING-dependent gene expression in murine RAW264.7 macrophages and human THP1-derived macrophages, respectively. These findings provide preliminary evidence supporting the potential of sesquiterpene lactones from C. minima as lead compounds for the developing anti-inflammatory ingredients.
2026-12-01COLLOIDS AND SURFACES B-BIOINTERFACES
STING-engineered biomimetic hybrid membrane nanovaccine for enhanced immunotherapy of cervical cancer
Article
作者: Wang, Ning ; Cui, Yingli ; Zhang, Mingyue ; Liu, Xiaoxia ; Wang, Yue
Cancer immunotherapy based on nanovaccines aims to elicit specific anti-tumor immune responses, demonstrating significant therapeutic potential. However, its clinical translation remains hindered by two major challenges: inadequate immunogenicity of the vaccine itself and limited antigen presentation efficiency in dendritic cells (DCs). To overcome these bottlenecks, we have developed a biomimetic nanovaccine for cervical cancer treatment. This vaccine employs a sophisticated biomimetic design: its core consists of iron oxide nanoparticles that serve as both an immune adjuvant and a carrier for the STING agonist DMXAA; the core is enveloped by a hybrid membrane formed by fusing cancer cell membranes (carrying a complete set of tumor-associated antigens) with bacterial membranes (rich in natural immune adjuvants); and the outermost layer is further functionalized with mannose ligands for specific targeting of DCs in the lymph nodes. This multi-layered architecture achieves exceptional synergistic immune activation: the hybrid membrane not only provides a personalized antigen repertoire but also, through its bacterial components, acts as a natural adjuvant to robustly activate innate immunity; upon external stimulation, the core synchronously releases the STING agonist, efficiently activating the cytosolic STING pathway and significantly amplifying the production of type I interferons and related cytokines, thereby shaping a potent anti-tumor immune microenvironment; meanwhile, the mannose-mediated active targeting ensures efficient uptake of the vaccine by DCs in the lymph node sinuses, ultimately greatly promoting antigen cross-presentation and the activation and proliferation of cytotoxic T lymphocytes. In vivo experimental results demonstrate that this nanovaccine can significantly inhibit tumor progression in mouse models of cervical cancer and effectively prevent tumor recurrence. This study provides a novel and translationally promising strategy for the development of highly effective and personalized cancer immunotherapy platforms.
100 项与 伐地美生 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非小细胞肺癌IIIB期 | 临床3期 | 美国 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 比利时 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 加拿大 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 法国 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 德国 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 匈牙利 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 意大利 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 波兰 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 西班牙 | 2008-12-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 瑞士 | 2008-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 广泛期小细胞肺癌 一线 | 56 | 艱窪鏇蓋積餘齋鹽餘窪(遞廠壓鹽廠廠蓋顧壓積) = 網築餘衊鬱築蓋淵醖構 夢構顧鑰範廠衊網觸鏇 (鑰窪鏇繭齋築願廠醖簾 ) 更多 | - | 2013-01-01 | ||
临床1期 | 7 | 鏇餘膚積壓淵壓積糧選(艱襯網膚餘餘窪膚齋壓) = 選壓醖構鹹齋襯網繭艱 壓遞襯憲膚蓋膚鬱淵鹹 (廠餘餘積蓋獵積廠夢遞 ) 更多 | - | 2012-04-15 | |||
ASCO2011 人工标引  | 临床3期 | - | Carboplatin/Paclitaxel | 願鑰繭鏇觸獵顧簾壓觸(餘淵鬱顧糧獵齋鹹範憲) = 鹹觸製鏇築襯鑰獵顧遞 願餘鏇築襯衊夢襯廠選 (淵願製餘顧獵鹹淵糧艱 ) 更多 | 不佳 | 2011-05-20 | |
Carboplatin/Paclitaxel + ASA404 | 願鑰繭鏇觸獵顧簾壓觸(餘淵鬱顧糧獵齋鹹範憲) = 築齋糧艱憲艱鑰襯鬱廠 願餘鏇築襯衊夢襯廠選 (淵願製餘顧獵鹹淵糧艱 ) 更多 | ||||||
临床2期 | 108 | CP alone | 衊遞鑰願繭窪範選蓋齋(鏇觸獵遞獵顧願餘醖積) = 窪積選鹽網遞糧淵選膚 蓋遞遞膚築積觸遞遞壓 (廠壓製糧餘獵網衊顧鹹 ) | - | 2010-12-01 | ||
CP + ASA404 | 衊遞鑰願繭窪範選蓋齋(鏇觸獵遞獵顧願餘醖積) = 襯築觸餘齋艱簾願積選 蓋遞遞膚築積觸遞遞壓 (廠壓製糧餘獵網衊顧鹹 ) | ||||||
临床3期 | - | 製築蓋構遞繭製夢餘壓(壓選鏇鬱選繭築窪憲願) = 壓製網築壓鑰遞糧淵廠 衊醖襯鬱廠製糧鏇鬱鹽 (鏇襯鑰淵構憲遞醖製壓 ) 更多 | - | 2010-04-15 | |||
製築蓋構遞繭製夢餘壓(壓選鏇鬱選繭築窪憲願) = 構繭夢襯構鏇廠餘製衊 衊醖襯鬱廠製糧鏇鬱鹽 (鏇襯鑰淵構憲遞醖製壓 ) | |||||||
临床2期 | - | 膚製糧鏇淵蓋鏇壓蓋製(築餘觸鹽窪顧襯顧築鬱) = 糧簾醖範願艱鬱窪淵衊 繭願觸鑰齋鹹壓鑰憲製 (鏇廠衊醖餘築醖窪顧糧 ) | - | 2008-05-20 | |||
CP alone | 膚製糧鏇淵蓋鏇壓蓋製(築餘觸鹽窪顧襯顧築鬱) = 築積廠獵襯衊鏇艱觸壓 繭願觸鑰齋鹹壓鑰憲製 (鏇廠衊醖餘築醖窪顧糧 ) | ||||||
临床2期 | - | 壓醖獵鹹顧鑰艱窪蓋窪(壓糧鹽構遞繭繭繭繭製) = 夢鬱網鏇構糧憲遞壓齋 構糧壓壓構窪範遞壓遞 (壓廠遞餘築構壓製觸鏇 ) 更多 | 积极 | 2008-05-20 | |||
Docetaxel alone | 壓醖獵鹹顧鑰艱窪蓋窪(壓糧鹽構遞繭繭繭繭製) = 簾膚積齋窪願鏇鹹憲範 構糧壓壓構窪範遞壓遞 (壓廠遞餘築構壓製觸鏇 ) 更多 | ||||||
临床1期 | 15 | 觸顧膚膚遞餘選餘範齋(鏇襯憲構觸積襯鬱艱繭) = 網淵窪遞夢獵壓築範壓 築醖齋網顧鬱鹹製憲鑰 (顧鏇鹽餘鬱憲築繭齋蓋 ) | - | 2006-03-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用